Karyopharm Therapeutics | KPTI - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
AbbVie USD 12.54B 474M 2026-03
Abbott USD 5.86B 675M 2026-03
Amgen USD 6.89B 415M 2025-12
AstraZeneca USD 12.61B 225M 2026-03
BioCryst Pharmaceuticals USD 153.05M 4.16M 2025-12
Bristol-Myers Squibb USD 8.41B 381M 2025-12
Eli Lilly USD 15.92B 1.33B 2025-12
Enanta Pharmaceuticals -22.29M 23.75M 2024-12
GlaxoSmithKline GBP 5.75B 429M 2026-03
Incyte USD 1.17B 217.51M 2026-03
J&J USD 17.24B 642M 2026-03
Karyopharm Therapeutics USD 32.6M 63.38M 2025-12
MacroGenics USD 31.11M 30.14M 2025-12
Merck USD 10.85B 2.57B 2025-12
Nektar Therapeutics USD 21.81M 8.06M 2025-12
Novartis USD 10.07B 184M 2026-03
Novartis USD 10.82B 694M 2025-09
Pfizer USD 12.28B 8.74B 2025-12
Regeneron Pharmaceuticals USD 2.94B 363.7M 2026-03
Roche Holding CHF 22.09B 10.04B 2025-12
Sangamo BioSciences -2.39M 1.09M 2024-06
Takeda JPY 790.55B 262.97B 2025-12
Tectonic Therapeutic USD 0 0 2025-03
TG Therapeutics USD 154.43M 20.81M 2025-12
Ultragenyx Pharmaceutical USD 178M 46.06M 2025-12
Xencor USD 21M 22.61M 2025-09